CSPC Pharmaceutical Group Limited CSPCY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 3.59B | -- | 3.63B | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 3.59B | -- | 3.63B | -- |
| Cost of Revenue | -- | 1.24B | -- | 1.23B | -- |
| Gross Profit | -- | 2.34B | -- | 2.41B | -- |
| SG&A Expenses | -- | 1.03B | -- | 1.06B | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 3.10B | -- | 3.05B | -- |
| Operating Income | -- | 481.66M | -- | 583.09M | -- |
| Income Before Tax | -- | 583.34M | -- | 711.07M | -- |
| Income Tax Expenses | -- | 123.09M | -- | 147.33M | -- |
| Earnings from Continuing Operations | -- | 460.25 | -- | 563.74 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -1.23M | -- | -1.51M | -- |
| Net Income | -- | 459.02M | -- | 562.23M | -- |
| EBIT | -- | 481.66M | -- | 583.09M | -- |
| EBITDA | -- | 643.06M | -- | 737.46M | -- |
| EPS Basic | -- | 0.04 | -- | 0.05 | -- |
| Normalized Basic EPS | -- | 0.03 | -- | 0.04 | -- |
| EPS Diluted | -- | 0.04 | -- | 0.05 | -- |
| Normalized Diluted EPS | -- | 0.03 | -- | 0.04 | -- |
| Average Basic Shares Outstanding | -- | 45.65B | -- | 45.86B | -- |
| Average Diluted Shares Outstanding | -- | 45.65B | -- | 45.86B | -- |
| Dividend Per Share | -- | 0.04 | -- | 0.03 | -- |
| Payout Ratio | -- | -- | -- | -- | -- |